According to FutureWise analysis, the immuno-oncology market in 2025 is US$32.45 billion, and is expected to reach US$124.9 billion by 2033 at a CAGR of 18.35%. The Immuno-Oncology market is experiencing rapid growth due to the increasing global burden of cancer and the rising success of immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies. Advances in precision medicine and biomarker research are facilitating the development of more targeted and effective treatments. Strategic collaborations between biotech firms and pharmaceutical companies are accelerating the drug development process. Furthermore, regulatory approvals for novel therapies and expanded indications are contributing to market expansion across various cancer types. Cancer immunotherapy, also known as immuno-oncology, is a treatment approach that utilizes the body's own immune system to prevent, eliminate, and control cancer. Boosting your immune system, providing your body with additional components to enhance the immunological response, and teaching your body to recognize and fight specific cancer cells can also aid in the elimination of cancer. In cancer immunotherapy, several therapies are available, including targeted antibodies, cancer vaccines, adoptive cell transfer, tumor-infecting viruses, checkpoint inhibitors, cytokines, and adjuvants. Immunotherapies are a type of biotherapy (also known as biologic therapy or biological response modifier (BRM) therapy), which uses compounds from living organisms to treat disease. The Department of Immuno-Oncology is at the forefront of medical research that uses the body's immune system to combat cancer. Due to its potential to utilize the body's built-in immunity to infection, immunotherapy is a significant tool in the fight against cancer. T-cell treatment, which employs specialized immune system cells to target and eliminate cancer cells, and immune checkpoint blockade, which modifies or strengthens the immune system to attack and eradicate tumor cells, are two cancer immunotherapies currently in use. For some people with metastatic cancer, these treatments work. But, researchers in the Department of Immuno-Oncology envision immunotherapy playing a much more significant role in the fight against cancer. By making immunotherapy a highly effective first-line treatment option that can lead to more potent and less toxic treatments, scientists aim to advance immunotherapy to the forefront. To treat patients with early-stage cancer and remove the microscopic residual disease that might cause cancer to return even after chemotherapy, radiation therapy, and surgery have been successful, researchers are aiming to improve the effectiveness of these innovative medicines further.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Immuno-Oncology Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=10981&type=requestsample

By Product Class

• Monoclonal Antibodies
  • Naked Monoclonal Antibodies
• Rituxan (Rituximab)
• Avastin (Bevacizumab)
• Herceptin (Trastuzumab)
• Conjugated Monoclonal Antibodies
  • ADCETRIS (Brentuximab vedotin)
  • Kadcyla (Ado-trastuzumab emtansine/TDM-1)
• Bispecific Monoclonal Antibodies
• Blincyto (Blinatumomab)
• Others
• Therapeutic Vaccines
• Provenge
• Immune Checkpoint Inhibitors
  • CTLA-4 Inhibitors (Cytotoxic T-lymphocyte-associated Protein-4)
    • Yervoy (Ipilimumab)
  • PD-1 and PD-L1 Inhibitors (Programmed Death 1 and Programmed Death Ligand)
  • Opdivo (Nivolumab)
  • Keytruda (Pembrolizumab)
  • Others

By Major Indications

• Head And Neck Cancer
• Lung Cancer
• Melanoma
• Lymphoma
• Leukemia
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Immuno-Oncology Market:

• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb
• MerckCo Co., Inc.
• Novartis
• AstraZeneca Plc
• Pfizer Inc
• Eli Lilly and Company
• Johnson And Johnson
• Amgen Inc.

Recent developments by key players in the Immuno-Oncology Market:

AstraZeneca Plc:

• AstraZeneca has made a strategic acquisition of Esobiotec for a potential total of $1 billion. This move aims to enhance its in vivo cell therapy innovations, thereby accelerating the development of its cell-based immuno-oncology pipeline.

MerckCo., Inc.:

• Merck Co. is making waves with its recent approvals in China for the first-line treatment of non-small cell lung cancer (NSCLC). This groundbreaking therapy is not only expanding its global footprint but also solidifying its position as the go-to choice in PD-1 therapy. The landscape of cancer treatment is evolving, and Keytruda is at the forefront.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10981&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Immuno-Oncology Market By Product Class, By Major Indications and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com